Moderna price target lowered to $186 from $188 at Chardan

Chardan analyst Geulah Livshits lowered the firm’s price target on Moderna to $186 from $188 and keeps a Buy rating on the shares after the company reported Q3 and reiterated upcoming data readouts from its respiratory and personalized cancer vaccine program are expected later this year. While the near-term value is "dominated by Covid," several added modalities and programs in the company’s pipeline have relevant catalysts that are positioned to support longer term value as proof of concepts emerge, Livshits tells investors.